FMO5 and glomerulosclerosis: This hypothesis is supported by previous work showing reduced NADPH oxidase activity and nitrotyrosine levels in a glomerulosclerosis mouse model either knocked-out for RAGE or treated with soluble RAGEs (sRAGEs) (Guo et al., 2008).